Check Out Our Animated Take on the Realities of a "No-deal" Brexit
Our animation explores the challenges that a "no-deal" Brexit poses for the drug development and advanced therapy sectors.
Back in February we wrote that "hard Brexit looks more likely than ever." Four months later: i) the Withdrawal Agreement (WA) has been rejected in the UK House of Commons for a third time, ii) both candidates for Prime Minister are promising to renegotiate the WA and, if the EU isn’t forthcoming, to leave the EU on October 31 without a deal; and iii) EU leaders are now making it clear that there will be no renegotiation of the WA – and they will not consider another Article 50 extension for the purpose of reopening negotiations on the WA. In short, a hard Brexit appears to be more likely than before.
Our animation covers the basics of how a no-deal Brexit might impact drug developers in the advanced medicines space. For more information, read the full article here.
You can also explore how a no-deal Brexit might impact supply chains.
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.
From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
